Hyderabad-Based NiedlFree Develops a Pain-Free Oral Insulin Spray for Diabetic Patients

Ozulin can be directly used into the mouth, by both animals and humans. The spray is going to help the country significantly which has been grappling with rising diabetes cases.

Hyderabad-based NiedlFree Technologies, a company affiliated with Transgene Biotek has developed a painless and needle-free oral insulin spray called Ozulin.

Ozulin is going to help the country significantly which has been grappling with rising diabetes cases. Besides, it mitigates the pain and inconvenience factors the diabetes insulin shots cause.

Further, this oral spray is a needle-free alternative for regulating blood glucose. It can be sprayed directly into the mouth and can be used by both animals and humans.

Further, the company has applied to the Central Drugs Standard Control Organisation (CDSCO) for approval to conduct safety and toxicology studies. Thereafter it will proceed with human trials.

Reportedly, Ozulin is set to hit the market around the year 2025-26. Further, it obtained global patents for Ozulin in over 40 countries.

In addition to diabetes treatment, NiedlFree Technologies is also working on developing oral and nasal sprays for cancer, osteoporosis, and Alzheimer's. To bring these drugs to the market, NiedlFree plans to raise $225-250 million in funding over the next few years.

In a recent study conducted by Palamur Biosciences on dogs, Ozulin demonstrated a bioavailability of over 91% compared to injectable insulin. This promising result indicates the effectiveness of the oral insulin spray.

Bioavailability is the degree and rate at which a substance (such as a drug) is absorbed into a living system or is made available at the site of physiological activity.

Founded in 2021, by Hyderabad-based Dr K Koteswara Rao, NiedlFree Technologies covers various segments of medical treatment such as diabetes, cancer, osteoporosis, and Alzheimer among others.

A recent study conducted by MediBuddy reveals that pre-diabetes affects a staggering 32.5% of the population. The number showed the importance of early diagnosis and diabetes management. The data also exposes a stark gender disparity, with approximately 13.7% of diabetes patients being male, while only 5.3% are female.

Days back, to curb the diabetic cases in the country, multinational pharma player, Dr Reddy’s Laboratories launched its first D2C e-commerce website ‘Celevida Wellness’ for diabetes patients by its wholly-owned subsidiary, Svaas Wellness Limited. The D2C platform hosts the Celevida range of products as well as other third-party brands to offer a product portfolio that takes care of a diabetic patient’s daily nutritional requirements.